Pular para o conteúdo principal
Ranking Invest

NMRA - Neumora Therapeutics, Inc. Common Stock

Segmento: HealthcareNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Análise Ranking Invest

Valuation estimado
-22,96%
-$ 749.67 Mi
Valor de Mercado
$ 195.41 Mi
Desconto (AV)-126.1%
IVR
-3.84A companhia vale -3,84 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-4.10O valuation alternativo equivale a -410% do valor de mercado da companhia.
MLL
-4.10O lucro líquido dos controladores em 16 trimestres equivale a -410% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 44.52 Mi

Dívida Líquida

-$ 63.92 Mi

L4T

-$ 212.75 Mi

Indicadores Básicos

ROE

-477.87%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.23

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

E-3.42

Margem

D0.00

Índices de Endividamento

DIV/PAT

-1.44

DIV/L4T

0.30

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.